Zevalin Y-90 Good as Frontline Therapy in Advanced Follicular Lymphoma

The results of an international, multicenter phase II trial evaluating the efficacy and toxicity of fractionated 90Y-ibritumomab tiutetan (otherwise known as Zevalin) for patients with advanced follicular lymphoma indicate that the radioimmunotherapy (RIT) is an effective frontline therapy for these patients.

Y-90 Zevalin is a very convenient and effective form of therapy for lymphoma patients compared to traditional combination chemotherapy. Currently, Y-90 Zevalin is approved for the treatment of recurring, low-grade or follicular B-cell non-Hodgkin's lymphoma following the failure of at least one other treatment regimen, and for the treatment of newly diagnosed follicular lymphoma after a response to other frontline therapy.

This study is likely attempting to pave the way for Y-90 Zevalin to be approved as a frontline therapy in advanced stage follicular lymphoma.

Administering treatment

The study, by Tim M. Illidge, University of Manchester, Manchester Academic Health Sciences Centre, Wilmslow Road, Manchester U.K. and colleagues, recruited 74 patients with a median age of 61 years (ranging from age 28 to 80), 78 percent of whom were diagnosed with stage III-IV disease. Of these patients, 32 percent were considered intermediate, and 44 percent were considered high-risk according to the FLIPI (follicular lymphoma international prognostic index).

Patients were treated with two doses of 90Y-IT administered eight to 12 weeks apart. Those patients found to have at least 20 percent infiltration of bone marrow were given weekly infusions of rituximab for four weeks and then received RIT only if another check of their bone marrow revealed that infiltration had fallen below 20 percent.

This phase II trial's primary end point was an end to treatment response in the intention-to-treat population. Secondary objectives were safety and progression-free survival (PFS).

Examining response rates

After the study, researchers found the following results:

  • Initial overall response rate (ORR): 94.4 percent (68 of 72 patients)
  • Combined complete response (CR/CRu): 58.3 percent (42 of 72 patients). Nine patients subsequently improved response making an ORR of 95.8 percent (69 of 72 patients) and CR/CRu of 69.4 percent (50 of 72 patients).

After a follow-up, researchers found::

  • At a median follow-up of 3.1 years, the estimated three-year PFS is 58 percent
  • Treatment-free survival is 66 percent
  • Overall survival is 95 percent
  • Median PFS is 40.2 months. Thirty patients have experienced disease progression and 24 have required further treatment.

These findings were first presented at the ASH 2011 conference. The researchers are now reporting them in the Journal of Clinical Oncology.

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...